AllPennyStocks.com RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead

William Blair downgraded Ultragenyx to ‘Market Perform’ from ‘Outperform,’ stating the miss could have negative implications for Ultragenyx’s other Angelman syndrome trial.

Other Penny Stock Movers

From Bitcoin to Big League Sports
AI Data Centers Are Being Rewired. One Critical Metal Is Moving With Them
Canadian Gold Explorer Gains 17% as Final Assays Complete Maiden Resource Database
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top